CD274 and neoplasm: Even though some of checkpoint proteins (such as PD-L1) are expressed on the surfaces of both tumor and MDSCs and a few cancer patients show good long-lasting clinical effects after ICB treatment, immunotherapeutic resistance develops in the late stage of most solid tumors.